DOCSLIB.ORG

Rational Design of CYP3A4 Inhibitors: a One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Rational Design of CYP3A4 Inhibitors: a One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength International Journal of Molecular Sciences Article Rational Design of CYP3A4 Inhibitors: A One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength Eric R. Samuels 1 and Irina F. Sevrioukova 2,* 1 Department of Pharmaceutical Sciences, University of California, Irvine, CA 92697-3900, USA; [email protected] 2 Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697-3900, USA * Correspondence: [email protected]; Tel.: +1-949-824-1953 Abstract: Inhibition of the major human drug-metabolizing cytochrome P450 3A4 (CYP3A4) by pharmaceuticals and other xenobiotics could lead to toxicity, drug–drug interactions and other adverse effects, as well as pharmacoenhancement. Despite serious clinical implications, the structural basis and attributes required for the potent inhibition of CYP3A4 remain to be established. We utilized a rational inhibitor design to investigate the structure–activity relationships in the analogues of ritonavir, the most potent CYP3A4 inhibitor in clinical use. This study elucidated the optimal length of the head-group spacer using eleven (series V) analogues with the R1/R2 side-groups as phenyls or R1–phenyl/R2–indole/naphthalene in various stereo configurations. Spectral, functional and structural characterization of the inhibitory complexes showed that a one-atom head-group linker elongation, from pyridyl–ethyl to pyridyl–propyl, was beneficial and markedly improved K , s IC50 and thermostability of CYP3A4. In contrast, a two-atom linker extension led to a multi-fold decrease in the binding and inhibitory strength, possibly due to spatial and/or conformational Citation: Samuels, E.R.; constraints. The lead compound, 3h, was among the best inhibitors designed so far and overall, the Sevrioukova, I.F. Rational Design of CYP3A4 Inhibitors: A One-Atom strongest binder (Ks and IC50 of 0.007 and 0.090 µM, respectively). 3h was the fourth structurally Linker Elongation in Ritonavir-Like simpler inhibitor superior to ritonavir, which further demonstrates the power of our approach. Compounds Leads to a Marked Improvement in the Binding Strength. Keywords: CYP3A4; ligand binding; inhibitor design; crystal structure; structure–activity relations; Int. J. Mol. Sci. 2021, 22, 852. surface mutation https://doi.org/10.3390/ijms22020852 Academic Editor: Patrick M. Dansette Received: 15 December 2020 1. Introduction Accepted: 12 January 2021 Cytochrome P450 (CYP) enzymes are monooxygenases that mediate xenobiotic metabolism Published: 16 January 2021 and the synthesis of steroids, vitamins and fatty acids [1,2]. In humans, CYP3A4 is the major liver and intestinal P450 isoform with a large and malleable active site which can Publisher’s Note: MDPI stays neutral accommodate chemically diverse compounds. As a result, CYP3A4 clears the majority of with regard to jurisdictional claims in administered drugs along with other foreign compounds, such as environmental pollu- published maps and institutional affil- tants, insecticides and pesticides [3–5]. Drugs may serve not only as substrates but also iations. as inducers and inhibitors of CYP3A4 [6]. The inhibition of CYP3A4 is usually undesired, because it could lead to drug toxicity, drug–drug interactions and other serious adverse effects. However, when carefully controlled, CYP3A4 inhibition can improve therapeutic efficacy of drugs by slowing down their conversion to more water-soluble, readily excreted Copyright: © 2021 by the authors. metabolites. This beneficial pharmacoenhancing (boosting) effect is currently used for Licensee MDPI, Basel, Switzerland. the treatment of HIV infection, where potent CYP3A4 inhibitors, ritonavir (Figure1A) This article is an open access article and its derivative cobicistat, are co-administered with anti-HIV drugs that otherwise are distributed under the terms and quickly metabolized by CYP3A4 [7,8]. The discovery and utilization of ritonavir as a conditions of the Creative Commons pharmacoenhancer for HIV-protease inhibitors was a paradigm shift in the treatment of Attribution (CC BY) license (https:// HIV and helped transform the deadly infection into a chronic and manageable disease [9]. creativecommons.org/licenses/by/ 4.0/). Int. J. Mol. Sci. 2021, 22, 852. https://doi.org/10.3390/ijms22020852 https://www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 2 of 23 Int. J. Mol. Sci. 2021, 22, 852 paradigm shift in the treatment of HIV and helped transform the deadly2 of 22 infection into a chronic and manageable disease [9]. FigureFigure 1. Chemical1. Chemical structures structures of ritonavir of ritonavir (A), a highly (A), potent a highly CYP3A4 potent inhibitor CYP3A4 in clinical inhibitor use, and in clinical use, and thethe best best two two rationally rationally designed designed inhibitors inhibitors from series from IV [10 series](B,C ).IV The [10] R1 and(B,C R2).side-groups The R1 and are R2 side-groups are indicated.indicated. If the If centralthe central hydroxyl hydroxyl group of group ritonavir of is ritonavir removed, the is phenylremoved, side-groups the phenyl would side-groups be in would be R/Rin R/R configuration. configuration. Other areas that could benefit from in-depth inhibitory studies on CYP3A4 are the treatmentOther of chronic areas hepatitisthat could C virus benefit (HCV) from infection in-depth and the inhibitory development studies of CYP3A4- on CYP3A4 are the specifictreatment index inhibitors.of chronic HCV hepatitis infection isC a worldwidevirus (HCV) health infection issue with noand effective the ordevelopment of wellCYP3A4-specific tolerated treatments index available inhibitors. to date. ThroughHCV infection CYP3A4 inhibition,is a worldwide ritonavir health is able to issue with no ef- diminish the hepatic metabolism of co-administered anti-HCV drugs, enhance response rates,fective alleviate or well a pill tolerated burden, and treatments provide an available additional to barrier date. to Through the development CYP3A4 of inhibition, ri- resistance-associatedtonavir is able to variants diminish [11]. the The hepatic antifungal meta agentbolism ketoconazole, of co-administered on the other hand, anti-HCV drugs, wasenhance widely response used as an rates, index inhibitoralleviate of a CYP3A pill burden, enzymes and in in provide vivo and anin vitroadditionaldrug– barrier to the drugdevelopment interaction studies of resistance-associated but, due to high hepatotoxicity, variants its usage[11]. isThe now antifungal limited [12], agent with ketoconazole, ritonavir recommended as the best replacement [13]. on the other hand, was widely used as an index inhibitor of CYP3A enzymes in in vivo However, two major issues associated with ritonavir are off-target activities and poorand physicochemical in vitro drug–drug properties interaction [14]. Even thoughstudies cobicistat but, due has to higher high solubility, hepatotoxicity, better its usage is tolerabilitynow limited and fewer[12], with side effectsritonavir [8,15 ],recomm it inhibitsended CYP3A4 as the 2-fold best weaker replacement and has sim- [13]. ilar reactivityHowever, toward two other major drug-metabolizing issues associated CYPs [16with]. Thus, ritonavir the inhibitory are off-target studies activities and onpoor CYP3A4 physicochemical could help develop properties safer and [14]. more Even potent though pharmacoenhancers cobicistat has and higher index solubility, better inhibitors for in vivo and in vitro studies. Importantly, both ritonavir and cobicistat are chemicallytolerability complex and fewer molecules sidethat effects were [8,15], not developed it inhibits based CYP3A4 on the 2-fold 3D structure weaker of and has similar CYP3A4.reactivity Moreover, toward ritonavir other was drug-metabolizing originally designed asCY anPs HIV [16]. protease Thus, inhibitor, the inhibitory whose studies on abilityCYP3A4 to potently could inhibit help CYP3A4develop was safer purely and coincidental more potent [7]. Therefore, pharmacoenhancers we undertook a and index in- serieshibitors of studies for in to investigatevivo and whatin vitro structural studies. determinants Importantly, are needed both for ritonavir potent inhibi- and cobicistat are tion and whether the inhibitory potency of ritonavir, the most potent CYP3A4 inhibitor inchemically clinical use, complex could be further molecules improved that via were rational not structure-based developed based inhibitor on design. the 3D structure of DetailedCYP3A4. investigations Moreover, on theritonavir structure–activity was originally relationship designed (SAR) of ritonaviras an HIV analogues protease inhibitor, andwhose their ability interaction to withpotently CYP3A4 inhibit are also CYP3A4 important was from purely the basic coincidental science perspective, [7]. Therefore, we un- asdertook they could a clarifyseries the of inhibitory/ligand studies to investigate binding mechanism what structural and provide determinants deeper insight are needed for intopotent the plasticity inhibition and adaptabilityand whether of CYP3A4. the inhibitory potency of ritonavir, the most potent Our earlier studies on the analogues of desoxyritonavir (provided by Gilead Sci- ences)CYP3A4 demonstrated inhibitor that in clinical the association use, could of ritonavir-like be further molecules improved is driven via rational by heme structure-based coordinationinhibitor design. [17], identified Detailed pyridine investigations as the strongest on heme-ligatingthe structure–activity group [18] and relationship laid
Load more

Recommended publications
  • Impaired Hepatic Drug and Steroid Metabolism in Congenital Adrenal
    European Journal of Endocrinology (2010) 163 919–924 ISSN 0804-4643 CLINICAL STUDY Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency Dorota Tomalik-Scharte1, Dominique Maiter2, Julia Kirchheiner3, Hannah E Ivison, Uwe Fuhr1 and Wiebke Arlt School of Clinical and Experimental Medicine, Centre for Endocrinology, Diabetes and Metabolism (CEDAM), University of Birmingham, Birmingham B15 2TT, UK, 1Department of Pharmacology, University Hospital, University of Cologne, 50931 Cologne, Germany, 2Department of Endocrinology, University Hospital Saint Luc, 1200 Brussels, Belgium and 3Department of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, 89019 Ulm, Germany (Correspondence should be addressed to W Arlt; Email: [email protected]) Abstract Objective: Patients with congenital adrenal hyperplasia due to P450 oxidoreductase (POR) deficiency (ORD) present with disordered sex development and glucocorticoid deficiency. This is due to disruption of electron transfer from mutant POR to microsomal cytochrome P450 (CYP) enzymes that play a key role in glucocorticoid and sex steroid synthesis. POR also transfers electrons to all major drug- metabolizing CYP enzymes, including CYP3A4 that inactivates glucocorticoid and oestrogens. However, whether ORD results in impairment of in vivo drug metabolism has never been studied. Design: We studied an adult patient with ORD due to homozygous POR A287P, the most frequent POR mutation in Caucasians, and her clinically unaffected, heterozygous mother. The patient had received standard dose oestrogen replacement from 17 until 37 years of age when it was stopped after she developed breast cancer. Methods: Both subjects underwent in vivo cocktail phenotyping comprising the oral administration of caffeine, tolbutamide, omeprazole, dextromethorphan hydrobromide and midazolam to assess the five major drug-metabolizing CYP enzymes.
    [Show full text]
  • Nitric Oxide in Health and Disease of the Nervous System H-Y Yun1,2, VL Dawson1,3,4 and TM Dawson1,3
    Molecular Psychiatry (1997) 2, 300–310 1997 Stockton Press All rights reserved 1359–4184/97 $12.00 PROGRESS Nitric oxide in health and disease of the nervous system H-Y Yun1,2, VL Dawson1,3,4 and TM Dawson1,3 Departments of 1Neurology; 3Neuroscience; 4Physiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA Nitric oxide (NO) is a widespread and multifunctional biological messenger molecule. It mediates vasodilation of blood vessels, host defence against infectious agents and tumors, and neurotransmission of the central and peripheral nervous systems. In the nervous system, NO is generated by three nitric oxide synthase (NOS) isoforms (neuronal, endothelial and immunologic NOS). Endothelial NOS and neuronal NOS are constitutively expressed and acti- vated by elevated intracellular calcium, whereas immunologic NOS is inducible with new RNA and protein synthesis upon immune stimulation. Neuronal NOS can be transcriptionally induced under conditions such as neuronal development and injury. NO may play a role not only in physiologic neuronal functions such as neurotransmitter release, neural development, regeneration, synaptic plasticity and regulation of gene expression but also in a variety of neurological disorders in which excessive production of NO leads to neural injury. Keywords: nitric oxide synthase; endothelium-derived relaxing factor; neurotransmission; neurotoxic- ity; neurological diseases Nitric oxide is probably the smallest and most versatile NO synthases isoforms and regulation of NO bioactive molecule identified. Convergence of multi- generation disciplinary efforts in the field of immunology, cardio- vascular pharmacology, chemistry, toxicology and neu- NO is formed by the enzymatic conversion of the guan- robiology led to the revolutionary novel concept of NO idino nitrogen of l-arginine by NO synthase (NOS).
    [Show full text]
  • Cholesterol Metabolites 25-Hydroxycholesterol and 25-Hydroxycholesterol 3-Sulfate Are Potent Paired Regulators: from Discovery to Clinical Usage
    H OH metabolites OH Review Cholesterol Metabolites 25-Hydroxycholesterol and 25-Hydroxycholesterol 3-Sulfate Are Potent Paired Regulators: From Discovery to Clinical Usage Yaping Wang 1, Xiaobo Li 2 and Shunlin Ren 1,* 1 Department of Internal Medicine, McGuire Veterans Affairs Medical Center, Virginia Commonwealth University, Richmond, VA 23249, USA; [email protected] 2 Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China; [email protected] * Correspondence: [email protected]; Tel.: +1-(804)-675-5000 (ext. 4973) Abstract: Oxysterols have long been believed to be ligands of nuclear receptors such as liver × recep- tor (LXR), and they play an important role in lipid homeostasis and in the immune system, where they are involved in both transcriptional and posttranscriptional mechanisms. However, they are increas- ingly associated with a wide variety of other, sometimes surprising, cell functions. Oxysterols have also been implicated in several diseases such as metabolic syndrome. Oxysterols can be sulfated, and the sulfated oxysterols act in different directions: they decrease lipid biosynthesis, suppress inflammatory responses, and promote cell survival. Our recent reports have shown that oxysterol and oxysterol sulfates are paired epigenetic regulators, agonists, and antagonists of DNA methyl- transferases, indicating that their function of global regulation is through epigenetic modification. In this review, we explore our latest research of 25-hydroxycholesterol and 25-hydroxycholesterol 3-sulfate in a novel regulatory mechanism and evaluate the current evidence for these roles. Citation: Wang, Y.; Li, X.; Ren, S. Keywords: oxysterol sulfates; oxysterol sulfation; epigenetic regulators; 25-hydroxysterol; Cholesterol Metabolites 25-hydroxycholesterol 3-sulfate; 25-hydroxycholesterol 3,25-disulfate 25-Hydroxycholesterol and 25-Hydroxycholesterol 3-Sulfate Are Potent Paired Regulators: From Discovery to Clinical Usage.
    [Show full text]
  • Nitric Oxide Produced by Ultraviolet-Irradiated Keratinocytes Stimulates Melanogenesis
    Nitric oxide produced by ultraviolet-irradiated keratinocytes stimulates melanogenesis. C Roméro-Graillet, … , J P Ortonne, R Ballotti J Clin Invest. 1997;99(4):635-642. https://doi.org/10.1172/JCI119206. Research Article Ultraviolet (UV) radiation is the main physiological stimulus for human skin pigmentation. Within the epidermal-melanin unit, melanocytes synthesize and transfer melanin to the surrounding keratinocytes. Keratinocytes produce paracrine factors that affect melanocyte proliferation, dendricity, and melanin synthesis. In this report, we show that normal human keratinocytes secrete nitric oxide (NO) in response to UVA and UVB radiation, and we demonstrate that the constitutive isoform of keratinocyte NO synthase is involved in this process. Next, we investigate the melanogenic effect of NO produced by keratinocytes in response to UV radiation using melanocyte and keratinocyte cocultures. Conditioned media from UV-exposed keratinocytes stimulate tyrosinase activity of melanocytes. This effect is reversed by NO scavengers, suggesting an important role for NO in UV-induced melanogenesis. Moreover, melanocytes respond to NO-donors by decreased growth, enhanced dendricity, and melanogenesis. The rise in melanogenesis induced by NO-generating compounds is associated with an increased amount of both tyrosinase and tyrosinase-related protein 1. These observations suggest that NO plays an important role in the paracrine mediation of UV-induced melanogenesis. Find the latest version: https://jci.me/119206/pdf Nitric Oxide Produced by Ultraviolet-irradiated Keratinocytes Stimulates Melanogenesis Christine Roméro-Graillet, Edith Aberdam, Monique Clément, Jean-Paul Ortonne, and Robert Ballotti Institut National de la Santé et de la Recherche Médicale U385, Faculté de Médecine, 06107 Nice cedex 02, France Abstract lin-1 (ET-1),1 and GM-CSF by keratinocytes is upregulated after UV light exposure, and these peptides stimulate melanocyte Ultraviolet (UV) radiation is the main physiological stimu- growth (16–19).
    [Show full text]
  • TRANSLATIONALLY by AMPK a Dissertation
    CHOLESTEROL 7 ALPHA-HYDROXYLASE IS REGULATED POST- TRANSLATIONALLY BY AMPK A dissertation submitted to Kent State University in partial fulfillment of the requirements for the Degree of Doctor of Philosophy By Mauris E.C. Nnamani May 2009 Dissertation written by Mauris E. C. Nnamani B.S, Kent State University, 2006 Ph.D., Kent State University, 2009 Approved by Diane Stroup Advisor Gail Fraizer Members, Doctoral Dissertation Committee S. Vijayaraghavan Arne Gericke Jennifer Marcinkiewicz Accepted by Robert Dorman , Director, School of Biomedical Science John Stalvey , Dean, Collage of Arts and Sciences ii TABLE OF CONTENTS LIST OF FIGURES……………………………………………………………..vi ACKNOWLEDGMENTS……………………………………………………..viii CHAPTER I: INTRODUCTION……………………………………….…........1 a. Bile Acid Synthesis…………………………………………….……….2 i. Importance of Bile Acid Synthesis Pathway………………….….....2 ii. Bile Acid Transport..…………………………………...…...………...3 iii. Bile Acid Synthesis Pathway………………………………………...…4 iv. Classical Bile Acid Synthesis Pathway…..……………………..…..8 Cholesterol 7 -hydroxylase (CYP7A1)……..........………….....8 Transcriptional Regulation of Cholesterol 7 -hydroxylase by Bile Acid-activated FXR…………………………….....…10 CYP7A1 Transcriptional Repression by SHP-dependant Mechanism…………………………………………………...10 CYP7A1 Transcriptional Repression by SHP-independent Mechanism……………………………………..…………….…….11 CYP7A1 Transcriptional Repression by Activated Cellular Kinase…….…………………………...…………………….……12 v. Alternative/ Acidic Bile Acid Synthesis Pathway…………......…….12 Sterol 27-hydroxylase (CYP27A1)……………….…………….12
    [Show full text]
  • Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
    pharmaceutics Review Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice Malavika Deodhar 1, Sweilem B Al Rihani 1 , Meghan J. Arwood 1, Lucy Darakjian 1, Pamela Dow 1 , Jacques Turgeon 1,2 and Veronique Michaud 1,2,* 1 Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA; [email protected] (M.D.); [email protected] (S.B.A.R.); [email protected] (M.J.A.); [email protected] (L.D.); [email protected] (P.D.); [email protected] (J.T.) 2 Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada * Correspondence: [email protected]; Tel.: +1-856-938-8697 Received: 5 August 2020; Accepted: 31 August 2020; Published: 4 September 2020 Abstract: In an ageing society, polypharmacy has become a major public health and economic issue. Overuse of medications, especially in patients with chronic diseases, carries major health risks. One common consequence of polypharmacy is the increased emergence of adverse drug events, mainly from drug–drug interactions. The majority of currently available drugs are metabolized by CYP450 enzymes. Interactions due to shared CYP450-mediated metabolic pathways for two or more drugs are frequent, especially through reversible or irreversible CYP450 inhibition. The magnitude of these interactions depends on several factors, including varying affinity and concentration of substrates, time delay between the administration of the drugs, and mechanisms of CYP450 inhibition. Various types of CYP450 inhibition (competitive, non-competitive, mechanism-based) have been observed clinically, and interactions of these types require a distinct clinical management strategy. This review focuses on mechanism-based inhibition, which occurs when a substrate forms a reactive intermediate, creating a stable enzyme–intermediate complex that irreversibly reduces enzyme activity.
    [Show full text]
  • Potent Inhibition of Human Cytochrome P450 3A Isoforms by Cannabidiol: Role of Phenolic Hydroxyl Groups in the Resorcinol Moiety
    Life Sciences 88 (2011) 730–736 Contents lists available at ScienceDirect Life Sciences journal homepage: www.elsevier.com/locate/lifescie Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety Satoshi Yamaori a, Juri Ebisawa a, Yoshimi Okushima a, Ikuo Yamamoto b, Kazuhito Watanabe a,c,⁎ a Department of Hygienic Chemistry, Faculty of Pharmaceutical Sciences, Hokuriku University, Ho-3, Kanagawa-machi, Kanazawa 920-1181, Japan b Department of Hygienic Chemistry, School of Pharmaceutical Sciences, Kyushu University of Health and Welfare, 1714-1 Yoshino-machi, Nobeoka 882-8508, Japan c Organization for Frontier Research in Preventive Pharmaceutical Sciences, Hokuriku University, Ho-3, Kanagawa-machi, Kanazawa 920-1181, Japan article info abstract Article history: Aims: In this study, we examined the inhibitory effects of Δ9-tetrahydrocannabinol (Δ9-THC), cannabidiol Received 4 October 2010 (CBD), and cannabinol (CBN), the three major cannabinoids, on the activity of human cytochrome P450 (CYP) Accepted 10 February 2011 3A enzymes. Furthermore, we investigated the kinetics and structural requirement for the inhibitory effect of CBD on the CYP3A activity. Keywords: Main methods: Diltiazem N-demethylase activity of recombinant CYP3A4, CYP3A5, CYP3A7, and human liver Cannabidiol microsomes (HLMs) in the presence of cannabinoids was determined. Δ9-Tetrahydrocannabinol Key findings: Among the three major cannabinoids, CBD most potently inhibited CYP3A4 and CYP3A5 Cannabinol μ Δ9 CYP3A4 (IC50 =11.7and1.65 M, respectively). The IC50 values of -THC and CBN for CYP3A4 and CYP3A5 were higher μ Δ9 – μ CYP3A5 than 35 M. For CYP3A7, -THC, CBD, and CBN inhibited the activity to a similar extent (IC50 =23 31 M).
    [Show full text]
  • Potential Roles of Nitrate and Nitrite in Nitric Oxide Metabolism in the Eye Ji Won Park1, Barbora Piknova1, Audrey Jenkins2, David Hellinga2, Leonard M
    www.nature.com/scientificreports OPEN Potential roles of nitrate and nitrite in nitric oxide metabolism in the eye Ji Won Park1, Barbora Piknova1, Audrey Jenkins2, David Hellinga2, Leonard M. Parver3 & Alan N. Schechter1* Nitric oxide (NO) signaling has been studied in the eye, including in the pathophysiology of some eye diseases. While NO production by nitric oxide synthase (NOS) enzymes in the eye has been − characterized, the more recently described pathways of NO generation by nitrate ( NO3 ) and nitrite − (NO2 ) ions reduction has received much less attention. To elucidate the potential roles of these pathways, we analyzed nitrate and nitrite levels in components of the eye and lacrimal glands, primarily in porcine samples. Nitrate and nitrite levels were higher in cornea than in other eye parts, while lens contained the least amounts. Lacrimal glands exhibited much higher levels of both ions compared to other organs, such as liver and skeletal muscle, and even to salivary glands which are known to concentrate these ions. Western blotting showed expression of sialin, a known nitrate transporter, in the lacrimal glands and other eye components, and also xanthine oxidoreductase, a nitrate and nitrite reductase, in cornea and sclera. Cornea and sclera homogenates possessed a measurable amount of nitrate reduction activity. These results suggest that nitrate ions are concentrated in the lacrimal glands by sialin and can be secreted into eye components via tears and then reduced to nitrite and NO, thereby being an important source of NO in the eye. Te NO generation pathway from L-arginine by endogenous NOS enzymes under normoxic conditions has been central in identifying the physiological roles of NO in numerous biological processes1.
    [Show full text]
  • Aripiprazole Therapy and CYP2D6 Genotype
    NLM Citation: Dean L. Aripiprazole Therapy and CYP2D6 Genotype. 2016 Sep 22. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-. Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/ Aripiprazole Therapy and CYP2D6 Genotype Laura Dean, MD1 Created: September 22, 2016. Introduction Aripiprazole is an atypical antipsychotic used in the management of schizophrenia, bipolar disorder, major depressive disorder, irritability associated with autistic disorder, and treatment of Tourette’s disorder. The metabolism and elimination of aripiprazole is mainly mediated through two enzymes, CYP2D6 and CYP3A4. Approximately 8% of Caucasians, 3–8% of Black/African Americans and up to 2% of Asians cannot metabolize CYP2D6 substrates and are classified as “poor metabolizers” (1). The FDA-approved drug label for aripiprazole states that in CYP2D6 poor metabolizers, half of the usual dose should be administered. In CYP2D6 poor metabolizers who are taking concomitant strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin), a quarter of the usual dose should be used (Table 1) (2). Table 1. The FDA-recommended dose adjustments for aripiprazole in patients who are known CYP2D6 poor metabolizers and patients taking concomitant CYP2D6 inhibitors, CYP3A4 inhibitors, and/or CYP3A4 inducers (2016) Factors Dosage Adjustments for ABILIFY Known CYP2D6 Poor Metabolizers Administer half of usual dose Known CYP2D6 Poor Metabolizers taking concomitant strong CYP3A4 inhibitors (e.g., Administer a quarter of usual dose itraconazole, clarithromycin) Strong CYP2D6 (e.g., quinidine, fluoxetine, paroxetine) or CYP3A4 inhibitors (e.g., Administer half of usual dose itraconazole, clarithromycin) Strong CYP2D6 and CYP3A4 inhibitors Administer a quarter of usual dose Strong CYP3A4 inducers (e.g., carbamazepine, rifampin) Double usual dose over 1 to 2 weeks Table is adapted from a FDA-approved drug label for aripiprazole (2).
    [Show full text]
  • Nitric Oxide Signaling in Plants
    plants Editorial Nitric Oxide Signaling in Plants John T. Hancock Department of Applied Sciences, University of the West of England, Bristol BS16 1QY, UK; [email protected]; Tel.: +44-(0)117-328-2475 Received: 3 November 2020; Accepted: 10 November 2020; Published: 12 November 2020 Abstract: Nitric oxide (NO) is an integral part of cell signaling mechanisms in animals and plants. In plants, its enzymatic generation is still controversial. Evidence points to nitrate reductase being important, but the presence of a nitric oxide synthase-like enzyme is still contested. Regardless, NO has been shown to mediate many developmental stages in plants, and to be involved in a range of physiological responses, from stress management to stomatal aperture closure. Downstream from its generation are alterations of the actions of many cell signaling components, with post-translational modifications of proteins often being key. Here, a collection of papers embraces the differing aspects of NO metabolism in plants. Keywords: nitrate reductase; nitration; nitric oxide; reactive oxygen species; stress responses; S-nitrosation; S-nitrosylation; SNO-reductase; thiol modification 1. Introduction Nitric oxide (NO) is now well acknowledged as an instrumental signaling molecule in both plants and animals [1]. First recognized as important as a signal in the control of vascular tone [2], its role in plants came to prominence in the late 1990s [3–5]. The forty years of research into NO in plants has just been highlighted by a review by Kolbert et al. [6]. In plants, NO has been found to be involved in a wide range of developmental stages and physiological responses.
    [Show full text]
  • Simulation of Physicochemical and Pharmacokinetic Properties of Vitamin D3 and Its Natural Derivatives
    pharmaceuticals Article Simulation of Physicochemical and Pharmacokinetic Properties of Vitamin D3 and Its Natural Derivatives Subrata Deb * , Anthony Allen Reeves and Suki Lafortune Department of Pharmaceutical Sciences, College of Pharmacy, Larkin University, Miami, FL 33169, USA; [email protected] (A.A.R.); [email protected] (S.L.) * Correspondence: [email protected] or [email protected]; Tel.: +1-224-310-7870 or +1-305-760-7479 Received: 9 June 2020; Accepted: 20 July 2020; Published: 23 July 2020 Abstract: Vitamin D3 is an endogenous fat-soluble secosteroid, either biosynthesized in human skin or absorbed from diet and health supplements. Multiple hydroxylation reactions in several tissues including liver and small intestine produce different forms of vitamin D3. Low serum vitamin D levels is a global problem which may origin from differential absorption following supplementation. The objective of the present study was to estimate the physicochemical properties, metabolism, transport and pharmacokinetic behavior of vitamin D3 derivatives following oral ingestion. GastroPlus software, which is an in silico mechanistically-constructed simulation tool, was used to simulate the physicochemical and pharmacokinetic behavior for twelve vitamin D3 derivatives. The Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) Predictor and PKPlus modules were employed to derive the relevant parameters from the structural features of the compounds. The majority of the vitamin D3 derivatives are lipophilic (log P values > 5) with poor water solubility which are reflected in the poor predicted bioavailability. The fraction absorbed values for the vitamin D3 derivatives were low except for calcitroic acid, 1,23S,25-trihydroxy-24-oxo-vitamin D3, and (23S,25R)-1,25-dihydroxyvitamin D3-26,23-lactone each being greater than 90% fraction absorbed.
    [Show full text]
  • Drug Interactions with Smoke and Smoking Cessation Medications
    Drug Interactions with Smoke and Smoking Cessation Medications Paul Oh MD MSc FRCPC FACP Medical Director, Toronto Rehab Assistant Professor, Division of Clinical Pharmacology, University of Toronto Disclosures • Advisory Boards – Amgen, AstraZeneca, BMS, Janssen, Novartis, Pfizer, Sanofi • Research Funding – Heart & Stroke, CIHR • Professional Affiliations: – CACR, CCN, CDA Objectives • review pharmacokinetic principles – what is the disposition of a medication once ingested? • highlight the role of the drug metabolism cytochrome P450 system as a particular site for many important drug interactions • Case based discussion of common interactions – drug-drug (SCT) and drug-smoke Cased Based Questions 1. What is a “CYP” and what does it do? 2. How can a sinus infection make you pass out? 3. Why is this workout so painful? 4. How do cigarettes and coffee go together? 5. Why is quitting possibly hazardous to your drug health? 6. What makes someone with heart disease and depression slow down? Ingestion First-Pass Metabolism Gut Lumen Gut Wall Liver Fraction Fraction Absorbed Metabolized Portal Circulation Metabolism Metabolism Drug Metabolism in the Liver SYSTEMIC LIVER CIRCULATION Eliminated unchanged by the kidneys To the kidneys for PORTAL VEIN elimination Drug Metabolism in the Liver SYSTEMIC LIVER CIRCULATION Eliminated unchanged by the kidneys P-450 OH Phase I metabolism Phase II metabolism Glucuronide OH Phase II metabolism Sulfate To the kidneys for PORTAL VEIN elimination Hepatocytes Cytochrome P450 Overview of Pharmacology Concepts Cytochrome P450 System • Nomenclature: e.g., CYP3A4 – "CYP" = cytochrome P450 protein abbreviation – family; subfamily; isoform • The most important isoforms are CYP3A4, CYP2D6, CYP1A2 – anticipate drug interactions if prescribing drugs using these enzymes.
    [Show full text]